Systematic (IUPAC) name
Clinical data
Legal status
  • Uncontrolled
Routes Oral
CAS number
ATC code None
Chemical data
Formula C15H23ClN4O2 
Mol. mass 326.82 g/mol

Dazopride (AHR-5531) is an antiemetic and gastroprokinetic agent of the benzamide class which was never marketed.[1][2][3][4][5] It acts as a 5-HT3 receptor antagonist and 5-HT4 receptor agonist.[3][4][6] In addition to its gastrointestinal effects, dazopride facilitates learning and memory in mice.[7]

See also


  1. ^ Grant SC, Kris MG, Gralla RJ, Clark RA, Tyson LB (1993). "Dose-ranging evaluation of the substituted benzamide dazopride when used as an antiemetic in patients receiving anticancer chemotherapy". Cancer Chemotherapy and Pharmacology 31 (6): 442–4.  
  2. ^ Alphin RS, Proakis AG, Leonard CA, et al. (May 1986). "Antagonism of cisplatin-induced emesis by metoclopramide and dazopride through enhancement of gastric motility". Digestive Diseases and Sciences 31 (5): 524–9.  
  3. ^ a b Costall B, Domeney AM, Gunning SJ, et al. (July 1987). "The action of dazopride to enhance gastric emptying and block emesis". Neuropharmacology 26 (7A): 669–77.  
  4. ^ a b Costall B, Domeney AM, Naylor RJ, Tattersall FD (September 1987). "Emesis induced by cisplatin in the ferret as a model for the detection of anti-emetic drugs". Neuropharmacology 26 (9): 1321–6.  
  5. ^ David J. Triggle (1996). Dictionary of Pharmacological Agents. Boca Raton: Chapman & Hall/CRC.  
  6. ^ Villalón CM, den Boer MO, Heiligers JP, Saxena PR (January 1991). "Further characterization, by use of tryptamine and benzamide derivatives, of the putative 5-HT4 receptor mediating tachycardia in the pig". British Journal of Pharmacology 102 (1): 107–12.  
  7. ^ Montgomery, S. A.; Halbreich, Uriel (2000). Pharmacotherapy for mood, anxiety, and cognitive disorders. Washington, DC: American Psychiatric Press.